From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Jump to: navigation, search

Rotigotine is a dopamine agonist used for Parkinson's disease and restless leg syndrome (RLS) which is available only as a slow-release transdermal patch applied to the skin.[1][2] Rotigotine is also sold under the brand name Neupro.[1][3] Rotigotine is in the same class of drugs as ropinirole and pramipexole.[4]

Theory[edit | edit source]

Evidence[edit | edit source]

No clinicial trials have yet been carried out of rotigotine for patients with ME/CFS.

A single study of rotigotine for fibromyalgia had high dropout rates for both the drug and placebo, but did not appear to show a significant improvement in pain or other fibromyalgia symptoms at doses of 4mg or 8mg.[4][5]

There is inconsistent evidence of the effect of rotigotine on fatigue in Parkinson's disease.[6][7]

Clinicians[edit | edit source]

Risks and safety[edit | edit source]

Costs and availability[edit | edit source]

Notable studies[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

agonist A chemical that binds to the receptor and stimulates it's function, e.g., morphine is an opioid agonist that binds to the opioid receptor, reducing pain. The opposite of an antagonist.

The information provided at this site is not intended to diagnose or treat any illness.
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history.